NASDAQ:TNXP - Tonix Pharmaceuticals Stock Price, Forecast & News

Tonix Pharmaceuticals trades on the NASDAQ under the ticker symbol "TNXP."

Tonix Pharmaceuticals's stock reverse split on the morning of Wednesday, November 28th 2018. The 1-10 reverse split was announced on Tuesday, November 27th 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, November 27th 2018. An investor that had 100 shares of Tonix Pharmaceuticals stock prior to the reverse split would have 10 shares after the split.

Tonix Pharmaceuticals Holding Corp (NASDAQ:TNXP) announced its quarterly earnings data on Friday, November, 8th. The company reported ($5.69) earnings per share for the quarter, missing the consensus estimate of ($4.35) by $1.34. View Tonix Pharmaceuticals' Earnings History.

Tonix Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March 16th 2020. View Earnings Estimates for Tonix Pharmaceuticals.

1 analysts have issued 12-month price objectives for Tonix Pharmaceuticals' shares. Their forecasts range from $1.30 to $1.30. On average, they expect Tonix Pharmaceuticals' share price to reach $1.30 in the next year. This suggests a possible upside of 31.3% from the stock's current price. View Analyst Price Targets for Tonix Pharmaceuticals.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Tonix Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Tonix Pharmaceuticals.

Media stories about TNXP stock have been trending positive recently, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Tonix Pharmaceuticals earned a daily sentiment score of 2.7 on InfoTrie's scale. They also assigned media stories about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Tonix Pharmaceuticals.

Tonix Pharmaceuticals saw a increase in short interest in January. As of January 31st, there was short interest totalling 868,700 shares, an increase of 741.8% from the January 15th total of 103,200 shares. Based on an average daily trading volume, of 1,820,000 shares, the short-interest ratio is currently 0.5 days. Approximately 10.2% of the shares of the stock are sold short. View Tonix Pharmaceuticals' Current Options Chain.

Some companies that are related to Tonix Pharmaceuticals include BIOLINERX LTD/S (BLRX), Mateon Therapeutics (MATN), Novelion Therapeutics (NVLNF), Conatus Pharmaceuticals (CNAT), KITOV PHARMA LT/S (KTOV), Diffusion Pharmaceuticals (DFFN), Novelion Therapeutics (NVLN), Nemus Bioscience (NMUS), Heat Biologics (HTBX), Aytu Bioscience (AYTU), OTCMKTS:EMBI (EMBI), IMMURON LTD/S (IMRN), Novan (NOVN), Acerus Pharmaceuticals (ASPCF) and Cyclacel Pharmaceuticals (CYCC).

Based on aggregate information from My MarketBeat watchlists, some companies that other Tonix Pharmaceuticals investors own include Rite Aid (RAD), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Novavax (NVAX), Actinium Pharmaceuticals (ATNM), Onconova Therapeutics (ONTX), Sorrento Therapeutics (SRNE), Opko Health (OPK), T2 Biosystems (TTOO) and Synthetic Biologics (SYN).

Tonix Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include Acadian Asset Management LLC (0.46%). Company insiders that own Tonix Pharmaceuticals stock include Ernest Mario, Gregory M Sullivan, Jessica Edgar Morris, John B Rhodes and Seth Lederman. View Institutional Ownership Trends for Tonix Pharmaceuticals.

TNXP stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC. View Insider Buying and Selling for Tonix Pharmaceuticals.

Shares of TNXP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of TNXP stock can currently be purchased for approximately $0.99.

Tonix Pharmaceuticals has a market capitalization of $8.42 million. The company earns $-26,090,000.00 in net income (profit) each year or ($268.10) on an earnings per share basis. Tonix Pharmaceuticals employs 12 workers across the globe.View Additional Information About Tonix Pharmaceuticals.

The official website for Tonix Pharmaceuticals is http://www.tonixpharma.com/.

Tonix Pharmaceuticals' mailing address is 509 MADISON AVENUE SUITE 1608, NEW YORK NY, 10022. The company can be reached via phone at 212-980-9155 or via email at [email protected]